Cargando…

Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis

BACKGROUND: X-ray repair cross-complementing group 1 (XRCC1) protein plays an important role in the repair of DNA damage and adducts. Single nucleotide polymorphisms (SNPs) of XRCC1 are suspected to have some relationship with response to chemotherapy and overall survival of lung cancer. This meta-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Zhigang, Yin, Zhihua, Li, Xuelian, Wu, Wei, Guan, Peng, Zhou, Baosen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305620/
https://www.ncbi.nlm.nih.gov/pubmed/22339849
http://dx.doi.org/10.1186/1471-2407-12-71
_version_ 1782227110142672896
author Cui, Zhigang
Yin, Zhihua
Li, Xuelian
Wu, Wei
Guan, Peng
Zhou, Baosen
author_facet Cui, Zhigang
Yin, Zhihua
Li, Xuelian
Wu, Wei
Guan, Peng
Zhou, Baosen
author_sort Cui, Zhigang
collection PubMed
description BACKGROUND: X-ray repair cross-complementing group 1 (XRCC1) protein plays an important role in the repair of DNA damage and adducts. Single nucleotide polymorphisms (SNPs) of XRCC1 are suspected to have some relationship with response to chemotherapy and overall survival of lung cancer. This meta-analysis aimed to summarize published data on the association between the commonest SNPs of XRCC1 (Arg194Trp, C > T, rs1799782 and Arg399Gln, G > A, rs25487) and clinical outcome of lung cancer patients. METHODS: We retrieved the relevant articles from PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases. Studies were selected using specific inclusion and exclusion criteria. Primary outcomes included objective response (i.e., complete response + partial response vs. progressive disease + stable disease) and overall survival (OS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were estimated. All analyses were performed using the Stata software. RESULTS: Twenty-two articles were included in the present analysis. XRCC1 Arg194Trp and Arg399Gln polymorphisms were significantly associated with response to treatment in lung cancer patients. Patients with C/T genotype, T/T genotype and minor variant T allele at Arg194Trp were more likely to respond to platinum-based chemotherapy compared with those with C/C genotype (C/T vs. C/C: OR, 2.54; 95%CI, 1.95-3.31; T/T vs. C/C: OR, 2.06; 95%CI, 1.39-3.06; C/T+T/T vs. C/C: OR, 2.42; 95% CI, 1.88-3.10). For XRCC1 Arg399Gln, G/A genotype, A/A genotype and minor variant A allele were associated with objective response in all patients (G/A vs. G/G: OR, 0.67; 95%CI, 0.50-0.90; A/A vs. G/G: OR, 0.43; 95%CI, 0.25-0.73; A/A+G/A vs. G/G: OR, 0.63; 95%CI, 0.49-0.83). Both G/A and A/A genotypes of XRCC1 Arg399Gln could influence overall survival of lung cancer patients (G/A vs. G/G: HR, 1.23; 95%CI, 1.06-1.44; A/A vs. G/G: HR, 2.03; 95%CI, 1.20-3.45). Interaction analysis suggested that compared with the patients carrying C/T+T/T genotype at XRCC1 194 and G/G genotype at XRCC1 399, the patients carrying 194 C/C and 399 G/A+A/A or 194 C/C and 399 G/G genotype showed much worse objective response. CONCLUSIONS: Genetic polymorphisms in XRCC1 gene might be associated with overall survival and response to platinum-based chemotherapy in lung cancer patients.
format Online
Article
Text
id pubmed-3305620
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33056202012-03-16 Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis Cui, Zhigang Yin, Zhihua Li, Xuelian Wu, Wei Guan, Peng Zhou, Baosen BMC Cancer Research Article BACKGROUND: X-ray repair cross-complementing group 1 (XRCC1) protein plays an important role in the repair of DNA damage and adducts. Single nucleotide polymorphisms (SNPs) of XRCC1 are suspected to have some relationship with response to chemotherapy and overall survival of lung cancer. This meta-analysis aimed to summarize published data on the association between the commonest SNPs of XRCC1 (Arg194Trp, C > T, rs1799782 and Arg399Gln, G > A, rs25487) and clinical outcome of lung cancer patients. METHODS: We retrieved the relevant articles from PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases. Studies were selected using specific inclusion and exclusion criteria. Primary outcomes included objective response (i.e., complete response + partial response vs. progressive disease + stable disease) and overall survival (OS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were estimated. All analyses were performed using the Stata software. RESULTS: Twenty-two articles were included in the present analysis. XRCC1 Arg194Trp and Arg399Gln polymorphisms were significantly associated with response to treatment in lung cancer patients. Patients with C/T genotype, T/T genotype and minor variant T allele at Arg194Trp were more likely to respond to platinum-based chemotherapy compared with those with C/C genotype (C/T vs. C/C: OR, 2.54; 95%CI, 1.95-3.31; T/T vs. C/C: OR, 2.06; 95%CI, 1.39-3.06; C/T+T/T vs. C/C: OR, 2.42; 95% CI, 1.88-3.10). For XRCC1 Arg399Gln, G/A genotype, A/A genotype and minor variant A allele were associated with objective response in all patients (G/A vs. G/G: OR, 0.67; 95%CI, 0.50-0.90; A/A vs. G/G: OR, 0.43; 95%CI, 0.25-0.73; A/A+G/A vs. G/G: OR, 0.63; 95%CI, 0.49-0.83). Both G/A and A/A genotypes of XRCC1 Arg399Gln could influence overall survival of lung cancer patients (G/A vs. G/G: HR, 1.23; 95%CI, 1.06-1.44; A/A vs. G/G: HR, 2.03; 95%CI, 1.20-3.45). Interaction analysis suggested that compared with the patients carrying C/T+T/T genotype at XRCC1 194 and G/G genotype at XRCC1 399, the patients carrying 194 C/C and 399 G/A+A/A or 194 C/C and 399 G/G genotype showed much worse objective response. CONCLUSIONS: Genetic polymorphisms in XRCC1 gene might be associated with overall survival and response to platinum-based chemotherapy in lung cancer patients. BioMed Central 2012-02-17 /pmc/articles/PMC3305620/ /pubmed/22339849 http://dx.doi.org/10.1186/1471-2407-12-71 Text en Copyright ©2012 Cui et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Cui, Zhigang
Yin, Zhihua
Li, Xuelian
Wu, Wei
Guan, Peng
Zhou, Baosen
Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis
title Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis
title_full Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis
title_fullStr Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis
title_full_unstemmed Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis
title_short Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis
title_sort association between polymorphisms in xrcc1 gene and clinical outcomes of patients with lung cancer: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305620/
https://www.ncbi.nlm.nih.gov/pubmed/22339849
http://dx.doi.org/10.1186/1471-2407-12-71
work_keys_str_mv AT cuizhigang associationbetweenpolymorphismsinxrcc1geneandclinicaloutcomesofpatientswithlungcancerametaanalysis
AT yinzhihua associationbetweenpolymorphismsinxrcc1geneandclinicaloutcomesofpatientswithlungcancerametaanalysis
AT lixuelian associationbetweenpolymorphismsinxrcc1geneandclinicaloutcomesofpatientswithlungcancerametaanalysis
AT wuwei associationbetweenpolymorphismsinxrcc1geneandclinicaloutcomesofpatientswithlungcancerametaanalysis
AT guanpeng associationbetweenpolymorphismsinxrcc1geneandclinicaloutcomesofpatientswithlungcancerametaanalysis
AT zhoubaosen associationbetweenpolymorphismsinxrcc1geneandclinicaloutcomesofpatientswithlungcancerametaanalysis